Waiting for ongoing studies, according to current data, it is possible to affirm that GLP-1 agonists are effective and safe in PAD patients and should be considered to be the first choice in T2D with history or at high risk of PAD and limb complications. This evidence concerns the gene GCG and type 2 diabetes mellitus.